Day: September 29, 2020

Jersey City, NJ, Sept. 29, 2020 (GLOBE NEWSWIRE) — Verisk (Nasdaq:VRSK), a leading data analytics provider, announces the addition of Gen. Vincent Brooks to its board of directors, effective October 1. Brooks served in the U.S. Army for 42 years from his entry into West Point until his 2019 retirement as a four-star general. Most recently, Brooks was in command of all U.S. Forces in Korea, where he concurrently led the United Nations Command, and the Republic of Korea – U.S. Combined Forces Command, which was comprised of more than 650,000 Korean and American soldiers.Currently, he’s a principal with WestExec Advisors, a D.C.-based advisory firm that provides geopolitical expertise to businesses navigating high-risk and volatile international environments. Brooks is also a member of the Council on Foreign Relations.“General Brooks...

CAMBRIDGE, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) — Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that Laurence Turka, M.D., chief scientific officer, will participate in a fireside chat at the 7th Annual Jefferies Cell Therapy Summit on Monday, October 5, 2020, at 4:00 p.m. ET.A live audio webcast will be available on the Events and Presentations page within the Investors and Media section of the Rubius Therapeutics website. An archived replay will be accessible for 90 days following the event.About Rubius TherapeuticsContacts:InvestorsLori MelançonVice President, Corporate Communications and Investor Relations+1 (617) 949-5296lori.melancon@rubiustx.comDan Budwick1AB+1 (973)...

AURORA, Ill., Sept. 29, 2020 (GLOBE NEWSWIRE) — Westell Technologies, Inc. (NASDAQ: WSTL), a leading provider of high-performance network infrastructure solutions, announced that at the Annual Meeting on September 29, 2020, the Company’s stockholders voted to approve proposals authorizing the Board of Directors of the Company to amend the Company’s certificate of incorporation to effect a 1-for-1,000 reverse stock split of the Company’s Class A and Class B Common Stock, followed immediately by an 1,000-for-1 forward stock split (the “Transaction”). The reverse and forward stock splits will be effected on October 1, 2020 and the Company’s Class A Common Stock is expected to begin trading on the NASDAQ Capital Market on a post-forward stock split basis upon the opening of trading on October 2, 2020.As a result of the reverse stock...

DANBURY, Conn., Sept. 29, 2020 (GLOBE NEWSWIRE) — FuelCell Energy, Inc. (Nasdaq: FCEL) (“FuelCell Energy” or the “Company”) today announced the launch of an underwritten public offering of 31,000,000 shares of its common stock (the “Offering”). FuelCell Energy expects to grant the underwriters a 30-day option to purchase up to 4,650,000 additional shares of its common stock. FuelCell Energy intends to use the net proceeds from the Offering for project development, project financing, working capital support, and general corporate purposes. FuelCell Energy may also use a portion of the net proceeds from the Offering to pay the principal redemption price of and accrued dividends on preferred stock issued by one of the Company’s subsidiaries and to repay other outstanding debt.J.P. Morgan Securities LLC, Barclays Capital Inc., and Canaccord...

TOL2/3 inhibitor most advanced compound in novel target class with dual action in inflammatory diseasesPatient trials initiated with GLPG3970 in psoriasis, ulcerative colitis, and rheumatoid arthritisToledo class target to be disclosed at Toledo Roundtable on 27 October 2020Mechelen, Belgium; 29 September 2020, 22.01 CET – Galapagos NV (Euronext & NASDAQ: GLPG) announces dosing of a first patient in their psoriasis trial, one of three patient trials currently recruiting to evaluate efficacy and safety of Toledo compound GLPG3970. Furthermore, Galapagos plans to unveil the novel Toledo target class and share GLPG3970 Phase 1 data at its inaugural Toledo Roundtable to be held virtually on 27 October 2020.  “We are excited by the rapid progress of GLPG3970 in the clinic,” said Dr. Piet Wigerinck, Chief Scientific Officer at Galapagos....

TOL2/3-remmer; meest vergevorderde compound in nieuwe target-categorie met duale actie in ontstekingsziektenPatiëntenstudies opgestart met GLPG3970 in psoriasis, colitis ulcerosa, en reumatoïde artritisToledo target-klasse wordt voorgesteld tijdens Toledo Roundtable op 27 oktober 2020Mechelen, België; 29 september 2020, 22.01 CET – Galapagos NV (Euronext & NASDAQ: GLPG) kondigt de dosering van de eerste patiënt in zijn psoriasis-studie aan. Dit programma is onderdeel van drie patiëntenstudies, momenteel in de rekruteringsfase, die de werkzaamheid en veiligheid van het Toledo compound GLPG3970 onderzoeken. Galapagos plant ook de nieuwe Toledo target-klasse te onthullen en de GLPG3970 fase 1-data te delen tijdens zijn eerste Toledo Roundtable die virtueel zal doorgaan op 27 oktober 2020.“We zijn enthousiast over de snelle klinische...

SHANGHAI, China, Sept. 30, 2020 (GLOBE NEWSWIRE) — Jiayin Group Inc. (“Jiayin” or the “Company”) (NASDAQ: JFIN), a leading fintech platform in China, today announced that, further to the press release dated March 13, 2020, Geerong (HK) Limited (“Geerong”, formerly known as Jiayin (HK) Limited), an indirect wholly-owned subsidiary of the Company, has closed the acquisition of 35% equity interest in Keen Best Investment Limited (“Keen Best”) from China Smartpay Group Holdings Limited (“Smartpay”), a Cayman Islands incorporated company, whose shares are listed on GEM of The Stock Exchange of Hong Kong Limited (Stock code: 8325).On March 13, 2020, Geerong and another independent purchaser (“Purchasers”) entered into a share purchase agreement (the “SPA”) with Smartpay, pursuant to which, among others, Geerong agreed, subject to certain...

MIDDLETOWN, R.I., Sept. 29, 2020 (GLOBE NEWSWIRE) — During its 2020 virtual conference, the National Marine Electronics Association honored three products from KVH Industries, Inc., (Nasdaq: KVHI) for product excellence. KVH’s TracPhone® V3-HTS received NMEA’s Product of Excellence Award in the satellite communications antenna category; KVH’s TracVision® UHD7 received the Product of Excellence Award in the satellite TV antenna category; and KVH’s TracPhone LTE-1 received the Product of Excellence Award in the WiFi/Cellular Device category (tied with Wave Wi-Fi).“We are deeply grateful to the members of the National Marine Electronics Association for this recognition,” said Jim George, senior director of global leisure sales. “NMEA members are invaluable partners in educating consumers, installing systems, and supporting KVH products....

SUWON, Republic of Korea, Sept. 29, 2020 (GLOBE NEWSWIRE) — OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, presents two virtual posters of their on-going clinical research at the 16th Annual Meeting of the Oligonucleotide Therapeutics Society on September 27 – 30. The presentations will focus on the results of the Company’s proprietary asymmetric siRNA (asiRNA) study, which confirms the therapeutic effects of RNAi-based therapeutics in patients with hepatic diseases and age-related macular degeneration.The first virtual presentation, entitled “Asymmetric siRNA Therapeutics by OliX Pharmaceuticals,” showcases the use of siRNA in effectively delivering RNAi molecules to the liver using GalNAc platform technology. It highlights the potential utility of GalNAc-asiRNA accelerating the development...